Novel Approaches for Modeling of the A1 Adenosine Receptor and Its Agonist Binding Site

Proteins: Structure, Function and Genetics

Volumn 54, Issue 4, 2004, Pages 705-715

  Gutiérrez De Terán, Hugo ^a   Centeno, Nuria B ^a   Pastor, Manuel ^a   Sanz, Ferran ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Adenosine; Docking exploration; G protein coupled receptors; GRIND; Histidine protonation; Homology modeling; Human A1 receptor; Molecular dynamics; Structural water

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; G PROTEIN COUPLED RECEPTOR; RHODOPSIN;

ARTICLE; CHEMOMETRICS; DRUG BINDING SITE; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTON TRANSPORT; SEQUENCE ALIGNMENT; X RAY CRYSTALLOGRAPHY;

ADENOSINE; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CATTLE; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; HISTIDINE; HUMANS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY; PROTONS; RECEPTOR, ADENOSINE A1; WATER;

BOVINAE;

EID: 1542316348     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.10617     Document Type: Article

References (83)

1. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology: XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-552.
2. Horn F, van der Wenden EM, Oliveira L, AP IJ, Vriend G. Receptors coupling to G proteins: is there a signal behind the sequence? Proteins 2000;41:448-459.
3. Müller C, Stein B. Adenosine receptor antagonists: Structures and potential therapeutic applications. Curr Pharm Design 1996;2:501-530.
4. 1 adenosine receptors and their ligands: overview and recent developments. II Farmaco 2001;56:77-80.
5. Poulsen SA, Quinn RJ. Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem 1998;6:619-641.
6. Haas HL, Selbach O. Functions of neuronal adenosine receptors. Naunyn-Schmiedebergs Arch Pharmakol 2000;362:375-381.
7. Downey JM, Liu GS, Thornton JD. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc Res 1993;27:3-8.
8. 1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart. Circulation 1996;94:11376-11380.
9. 1 antagonists: 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure, J Med Chem 1992;35:3066-3075.
10. 1 adenosine receptor: an evaluation of the binding free-energy with ligands. Drug Des Discov 1998;15:149-156.
11. 1 adenosine receptor antagonists. J Med Chem 2001;44:316-327.
12. 1 adenosine receptor. J Biol Chem 1999;274:3617-3621.
13. 1 receptor and ligand molecular modelling. Drug Dev Res 1993;28:237-243.
14. 1 receptor. Drug Des Discov 1992;9:49-67.
15. 3 adenosine antagonists: structural homology and receptor docking. J Chem InfComput Sci 1998;38:1239-1248.
16. 2A adenosine receptors are required for ligand recognition. Mol Pharmacol 1996;50:512-521.
17. 2A adenosine receptor. J Biol Chem 1995;270:13987-13997.
18. 2A receptor. Eur J Pharmacol 1994;268: 95-104.
19. Henderson R, Baldwin JM, Ceska TA, Zemlin F, Beckmann E, Downing KH. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J Mol Biol 1990;213: 899-929.
20. Baldwin JM, Schertler GF, Unger VM. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 1997;272:144-164.
21. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor [see comments]. Science 2000;289:739-745.
22. Filipek S, Teller DC, Palczewski K, Stenkamp R. The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors. Annu Rev Biophys Biomol Struct 2003; 32:375-397.
23. 3 adenosine receptor and molecular modeling studies. J Med Chem 2001;44:2735-2742.
24. Jacobson KA, Gao ZG, Chen A, Barak D, Kim SA, Lee K, Link A, Rompaey PV, van Calenbergh S, Liang BT. Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. J Med Chem 2001;44:4125-4136.
25. 1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Mol Pharmacol 1996;50:1635-1642.
26. 1 adenosine receptor: studies on the ligand binding site by site-directed mutagenesis. J Biol Chem 1992;267:10764-10770.
27. 1 adenosine receptor mediates specific agonist binding. J Biol Chem 1994;269: 2373-2376.
28. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 1998;125:924-947.
29. Olah ME, Stiles GL. The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther 2000;85:55-75.
30. 1 adenosine receptor. Mol Pharmacol 2001;59:1187-1195.
31. 1 adenosine receptor with an antagonist photoaffinity probe. Mol Pharmacol 1996;50:789-798.
32. 1 adenosine receptor. J Neurochem 1993;60:1525-1533.
33. Gao ZG, Jiang Q, Jacobson KA, Ijzerman AP. Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of Glu(13) and His(278) in ligand binding and sodium modulation, Biochem Pharmacol 2000;60:661-668.
34. 2A receptor: critical involvement of Glu13 in agonist recognition. Eur J Pharmacol 1996;310:269-272.
35. Ballesteros JA, Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. In: Conn PM, Sealfon SC, editors. Methods in neurosciences. San Diego: Academic Press; 1994. p 366-428.
36. Bairoch A, Apweiler R., The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res 2000;28:45-48.
37. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL:X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-4882.
38. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
39. Persson B, Argos P. Prediction of membrane protein topology utilizing multiple sequence alignments. J Protein Chem 1997;16: 453-457.
40. Swiss-Prot. Available online at http://us.expasy.org
41. TMPRED. Available online at http://www.ch.embnet.org
42. Rost B, Sander C. Prediction of protein secondary structure at better than 70% accuracy. J Mol Biol 1993;232:584-599.
43. ld-adrenergic receptor activation: a molecular dynamics and docking study. Proteins 2001;43:382-394.
44. Blundell T, Barlow D, Borkakoti N, Thornton J. Solvent-induced distortions and the curvature of alpha-helices. Nature 1983;306: 281-283.
45. Insight II, Version 2000. San Diego: Simulations IM; 2000.
46. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 1995;117:5179-5197.
47. Case DA, Pearlman DA, Caldwell JW, et al. AMBER, Version 6. University of California, San Francisco; 1999.
48. Scheer A, Fanelli F, Costa T, De Benedetti P, Cotecchia S. Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J 1996;15:3566-3578.
49. Sealfon SC, Chi L, Ebersole BJ, Rodic V, Zhang D, Ballesteros JA, Weinstein H. Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J Biol Chem 1995;270:16683-16688.
50. Zhou W, Flanagan C, Ballesteros J, Konvicka K, Davidson J, Weinstein H, Millar R, Sealfon S. A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. Mol Pharmacol 1994;45:165-170.
51. Govaerts C, Lefort A, Costagliola S, Wodak SJ, Ballesteros JA, Van Sande J, Pardo L, Vassart G. A conserved Asn in transmembrane helix 7 Is an on/off switch in the activation of the thyrotropin receptor. J Biol Chem 2001;276:22991-22999.
52. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the Cartesian equation of motion of a system constraints: molecular dynamics of N-alkanes. J Compt Phys 1977;23:327-341.
53. Humphrey W, Dalke A, Schulten K. VMD-visual molecular dynamics. J Mol Graph Model 1996;14:33-38.
54. Marengo E, Todeschini R. A new algorithm for optimal, distance-based experimental design. Chemom Intell Lab Sys 1992;16:37-44.
55. GOLPE, Version 4.5. Perugia (Italy): Multivariate Infometric Analysis Srl. MIA; 2000.
56. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-291.
57. Hooft RW, Vriend G, Sander C, Abola EE. Errors in protein structures. Nature 1996;381:272.
58. Goodford PJ. A computational procedure for determining energetically favorable binding sites of biological important macromolecules. J Med Chem 1985;28:849-857.
59. Wade RC. Solvation of the active site of cytochrome P450-cam. J Comput-Aided Mol Des 1990;4:199-204.
60. Pastor M, Cruciani G, McLay I, Pickett S, Clementi S. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J Med Chem 2000;43:3233-3243.
61. ALMOND, Version 3.0. Perugia (Italy): Multivariate Infometric Analysis Srl. MIA; 2001.
62. Hodgkin E, Richards W. Molecular similarity based on electrostatic potential and electric field. Int J Quan Chem 1987;14:105-110.
63. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comp Chem 1998;19:1639-1662.
64. 3 adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. J Med Chem 2002;45:4471-4484.
65. Kenakin T, Onaran O. The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 2002;23:275-280.
66. 3 adenosine receptors. J Biol Chem 1994;269: 24692-24698.
67. 2A adenosine receptor are required for ligand recognition. Mol Pharmacol 1996;49:683-691.
68. Gao Z-G, Chen A, Barak D, Kim S-K, Muller CE, Jacobson KA. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem 2002;277:19056-19063.
69. Lomize AL, Pogozheva ID, Mosberg HI. Structural organization of G-protein-coupled receptors. J Comp Aid Mol Des 1999;13:325-353.
70. Gao ZG, Ijzerman AP. Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. Biochem Pharmacol 2000;60:669-676.
71. 1 adenosine receptors in rat brain membranes: evidence for histidine in different domains of the ligand binding site. J Biol Chem 1988;263:17522-17526.
72. Engh R, Huber R. Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallogr A 1991;47:392-400.
73. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci USA 2002;99:5982-5987.
74. Kristiansen K, Kroeze WK, Willins DL, Gelber EI, Savage JE, Glennon RA, Roth BL. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT2A serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. J Pharmacol Exp Ther 2000;293:735-746.
75. Müller CE. Adenosine receptor ligands-recent developments: Part I. Agonists. Curr Med Chem 2000;7:1269-1288.
76. Klotz KN. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol 2000;362:382-391.
77. RELIBase. Available online at http://relibase.ebi.ac.uk
78. Mahmoudian M. The cannabinoid receptor: computer-aided molecular modeling and docking of ligand. J Mol Graph Model 1997;15:149-153, 179.
79. Gieldon A, Kazmierkiewicz R, Slusarz R, Ciarkowski J. Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin Vla, V2 receptors and with oxytocin receptors. J Comput Aided Mol Des 2001;15:1085-1104.
80. Reeves DC, Sayed MF, Chau PL, Price KL, Lummis SC. Prediction of 5-HT(3) receptor agonist-binding residues using homology modeling. Biophys J 2003;84:2338-2334.
81. Cavasotto CN, Orry AJ, Abagyan RA. Structure-based identification of binding sites, native ligands and potential inhibitors for G-protein coupled receptors. Proteins 2003;51:423-433.
82. Javitch JA, Ballesteros JA, Weinstein H, Chen J. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. Biochemistry 1998;37:998-1006.
83. Marie J, Richard E, Pruneau D, Paquet JL, Siatka C, Larguier R, Ponce C, Vassault P, Groblewski T, Maigret B, Bonnafous JC. Control of conformational equilibria in the human B2 bradykinin receptor: modeling of nonpeptidic ligand action and comparison to the rhodopsin structure. J Biol Chem 2001;276:41100-41111.